Discover
RGLS
Regulus Therapeutics Inc.
8.16
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 416.46% | |
| 1y | 298.05% |
8.16
day range
8.16
52 week range
| Open | 8.15 | Prev Close | 8.16 | Low | 8.16 | High | 8.16 | Mkt Cap | N/A |
| Vol | 8.76M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -1.26 |
| Beta | 1.63 | Short Ratio | 3.38 | Inst. Own | 88.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 10.33 |
| Income Statement | |||
| Operating Expenses | 10.54M | ||
| Research and Development Expense | 6.82M | ||
| Selling, General and Administrative Expense | 3.72M | ||
| Operating Income | -10.54M | ||
| Interest Expense | 17.00K | ||
| Net Income | -9.63M | ||
| Net Income Common Stock | -9.63M | ||
| Net Income Common Stock (USD) | -9.63M | ||
| Consolidated Income | -9.63M | ||
| Earnings per Basic Share | -0.15 | ||
| Earnings per Basic Share (USD) | -0.15 | ||
| Earnings per Diluted Share | -0.15 | ||
| Earning Before Interest & Taxes (EBIT) | -9.62M | ||
| Earning Before Interest & Taxes (USD) | -9.62M | ||
| Weighted Average Shares | 66.17M | ||
| Weighted Average Shares Diluted | 66.17M | ||
| Balance Sheet | |||
| Cash and Equivalents | 49.52M | ||
| Cash and Equivalents (USD) | 49.52M | ||
| Investments | 15.91M | ||
| Investments Current | 15.91M | ||
| Current Assets | 71.69M | ||
| Property, Plant & Equipment Net | 3.11M | ||
| Total Assets | 74.83M | ||
| Total Debt | 1.40M | ||
| Current Liabilities | 4.40M | ||
| Debt Non-Current | 1.40M | ||
| Total Liabilities | 5.80M | ||
| Accumulated Retained Earnings (Deficit) | -569.21M | ||
| Accumulated Other Comprehensive Income | 10.00K | ||
| Shareholders Equity | 69.03M | ||
| Shareholders Equity (USD) | 69.03M | ||
| Assets Non-Current | 3.13M | ||
| Total Debt (USD) | 1.40M | ||
| Goodwill and Intangible Assets | 23.00K | ||
| Liabilities Non-Current | 1.40M | ||
| Trade and Non-Trade Payables | 200.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 85.00K | ||
| Net Cash Flow from Financing | 45.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 10.93M | ||
| Issuance (Purchase) of Equity Shares | 45.00K | ||
| Net Cash Flow from Investing | 21.50M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 21.50M | ||
| Net Cash Flow from Operations | -10.61M | ||
| Share Based Compensation | 2.25M | ||